AstraZeneca to buy blood cancer focused biotech in deal valued at up to $1.27bn July 5, 2022 Auto Bot Preclinical Research 0 AstraZeneca is to acquire US-based blood cancer specialist, TeneoTwo, in a deal worth around US$1.27bn.
